Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia
- 12 February 2020
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 198 (2) , 355-360
Abstract
Introduction Idiopathic chronic eosinophilic pneumonia (ICEP) is an orphan lung disease characterized by concomitant systemic and local eosinophilia, along with bilateral lung infiltrates. Symptoms include dyspnea of subacute/chronic onset, cough, and general systemic signs. Although all patients do respond to oral corticosteroids, relapse rate is very high, which highlights the need for alternative therapies in case of relapsing ICEP. Mepolizumab is a fully humanized antibody directed against interleukin 5, a key growth factor of eosinophils. In the present study, we retrospectively studied the effect of off-label use of mepolizumab for relapsing ICEP. Materials and Methods All data from patients treated with mepolizumab for relapsing ICEP were included in our database and diagnoses were reviewed. We analyzed the effect of treatment on relapse rate, oral corticosteroids (OCS) use, and lung lesions on high-resolution computed tomography (HRCT). Results We included ten patients in the final analysis, with a median follow-up of 9 months after initiation of mepolizumab. Beside its expected effect on circulating eosinophils, treatment with mepolizumab was associated with a significant reduction of annual rate of exacerbations and a reduced consumption of corticosteroids. We also observed a remission of lung lesions on follow-up HRCT. Conclusions In this open-label retrospective study, treatment of ICEP with mepolizumab was associated with a reduction of relapses, OCS use, and the disappearance of lung infiltrates.Keywords
This publication has 17 references indexed in Scilit:
- Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and managementAllergology International, 2019
- Eosinophilic PneumoniasThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- A case of chronic eosinophilic pneumonia successfully treated with mepolizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- The effect of corticosteroids on quality of life in a sarcoidosis clinic: The results of a propensity analysisRespiratory Medicine, 2015
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromesJournal of Allergy and Clinical Immunology, 2013
- Treatment of Patients with the Hypereosinophilic Syndrome with MepolizumabNew England Journal of Medicine, 2008
- Idiopathic Chronic Eosinophilic PneumoniaSeminars in Respiratory and Critical Care Medicine, 2006
- Idiopathic Chronic Eosinophilic Pneumonia: A Clinical and Follow-Up Study of 62 CasesMedicine, 1998